regulatory status raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Status varies by country; prohibited in sport. |
| Common storage temperature | 2–8 °C for lyophilized powder | Protect from light and moisture; follow supplier instructions. |
| Typical analytical method | LC-MS/MS | Used for identification and quantification in biological samples. |
| Purity assessment | HPLC and mass spectrometry | Reverse-phase HPLC is common for peptide purity. |
| Common synonyms | AOD9604; hGH 176-191 fragment | Naming conventions differ across studies. |
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
A wide branch of technology ethics is concerned with the ethics of artificial intelligence: it includes robot ethics, which deals with ethical issues involved in the design, construction, use, and treatment of robots, as well as machine ethics, which is concerned with ensuring the ethical behavior of artificially intelligent agents. Within the field of AI ethics, significant yet-unsolved research problems include AI alignment (ensuring that AI behaviors are aligned with their creators' intended goals and interests) and the reduction of algorithmic bias. Some researchers have warned against the hypothetical risk of an AI takeover, and they have advocated for the use of AI capability control in addition to AI alignment methods. Other fields of ethics have had to contend with technology-related issues, including military ethics, media ethics, and educational ethics.
== Further reading == Layinka Swinburne (1997). "Dancing with the Mermaids: Ship's Biscuit and Portable Soup". In Harlan Walker (ed.). Food on the Move: Proceedings of the Oxford Symposium on Food and Cookery, 1996. Prospect Books. ISBN 978-0-907325-79-6. Schroeder-Lein, G.R. (2015). The Encyclopedia of Civil War Medicine. Taylor & Francis. p. 228. ISBN 978-1-317-45709-1. Retrieved October 6, 2017.
What is absorbed is excreted in urine. Relatively large amounts of nickel – comparable to the estimated average ingestion above – leach into food cooked in stainless steel. For example, the amount of nickel leached after 10 cooking cycles into one serving of tomato sauce averages 88 μg. Nickel released from Siberian Traps volcanic eruptions is suspected of helping the growth of Methanosarcina, a genus of euryarchaeote archaea that produced methane in the Permian–Triassic extinction event, the biggest known mass extinction.
==== Parliamentary Commissioner for Standards ==== When the allegations against Galloway emerged in 2003, the UK parliament's Commissioner for Standards began investigating, as Galloway was a Member of Parliament and none of the alleged funding had been declared in the Register of Members' Interests. The Commissioner, Philip Mawer, was overseen by the Standards and Privileges Committee. After a four-year investigation, he published a detailed report in 2007, which concluded:
=== DNA repair === Two classical DNA repair pathways, nucleotide excision repair and base excision repair, are present in hydra, and these repair pathways facilitate unhindered reproduction. The identification of these pathways in hydra is based, in part, on the presence in the hydra genome of genes homologous to genes in other genetically well studied species that have been demonstrated to play key roles in these DNA repair pathways.
Sources: en.wikipedia.org
=== October === October 1 The US imposes new sanctions on Iran, targeting rail, automotive, manufacturing, and steel sectors, as well as overseas suppliers, saying that the goal is to economically isolate the Iranian government. The US military starts sending about 9,000 soldiers to the Middle East on naval ships, such as the USS Makin Island amphibious readiness group and the USS Theodore Roosevelt carrier strike group. October 2 The US imposes sanctions on Hamas' financing network, which includes two French-based funds. Alabama state representative Brett Easterbrook is arrested on charges of first-degree human trafficking and prostitution as part of a sting. At least a dozen other men are arrested. October 3 – Trump establishes a task force to examine the risks and opportunities of AI and recommend what role the federal government should play in overseeing the technology without compromising competitiveness with China. October 4 The State Department announces that the US "kicked out" two members of the Iranian delegation who attended the recent United Nations General Assembly after they ignored an order to leave the country long after the General Assembly had ended. Trump withdraws all US bombers from RAF Fairford, a British air base targeted by an attack that the UK linked to the Iranian government, due to urgent concerns about a potentially complex drone attack ordered by the IRGC as part of a plot to target the aircraft and kill American soldiers at RAF Fairford, which is loosely modeled after Ukraine's Operation Spiderweb.
=== CANDU reactors === Natural uranium, with 0.72% 235U, is usable as nuclear fuel in reactors designed specifically for this, such as the heavy-water CANDU reactor. By making use of non-enriched uranium, such reactor designs give a nation access to nuclear power for the purpose of electricity production without necessitating the development of fuel enrichment capabilities, which are often seen as a prelude to weapons production.
Orforglipron — brand name Foundayo — is an oral, non-peptide, small-molecule GLP-1 receptor agonist developed as a weight loss drug by Eli Lilly and Company. It was discovered by Chugai Pharmaceutical Co., then was licensed to Lilly in 2018. Orforglipron was approved for medical use in the United States in April 2026. It was approved for use in the UK in August 2026.
=== Fruits === Fruits with a wide variety of structural origins have converged to become edible. Apples are pomes with five carpels; their accessory tissues form the apple's core, surrounded by structures from outside the botanical fruit, the receptacle or hypanthium. Other edible fruits include other plant tissues; the fleshy part of a tomato is the walls of the pericarp. This implies convergent evolution under selective pressure, in this case the competition for seed dispersal by animals through consumption of fleshy fruits. Seed dispersal by ants (myrmecochory) has evolved independently more than 100 times, and is present in more than 11,000 plant species. It is one of the most dramatic examples of convergent evolution in biology.
=== Civil Police === The Civil Police consists of the Criminal Investigation Department (CID), Counter Insurgency Force (CIF), Enforcement Branch (EB), Intelligence Branch (IB), Traffic Branch, Police Telecommunications, Training Wing, State Crime Records Bureau (SCRB) & Police Computer Centre (PCC).
Sources: en.wikipedia.org
=== Insertion devices === Some pump users prefer to use an insertion device to insert their sets, rather than pushing the needle in by hand. These are spring-loaded and are designed to push the needle into the skin quickly. The user simply loads the primed set into the insertion device, peels off the paper protecting the adhesive pad, places the device against the skin and presses a button. This may be an advantage for those with needle phobia.
According to one report based on a treatment of 60 patients with silibinin, patients who started the drug within 96 hours of ingesting the mushroom and who still had intact kidney function all survived. As of February 2014 supporting research has not yet been published. SLCO1B3 has been identified as the human hepatic uptake transporter for amatoxins; moreover, substrates and inhibitors of that protein—among others rifampicin, penicillin, silibinin, antamanide, paclitaxel, ciclosporin and prednisolone—may be useful for the treatment of human amatoxin poisoning. N-Acetylcysteine has shown promise in combination with other therapies. Animal studies indicate the amatoxins deplete hepatic glutathione; N-acetylcysteine serves as a glutathione precursor and may therefore prevent reduced glutathione levels and subsequent liver damage. None of the antidotes used have undergone prospective, randomized clinical trials, and only anecdotal support is available. Silibinin and N-acetylcysteine appear to be the therapies with the most potential benefit. Repeated doses of activated carbon may be helpful by absorbing any toxins returned to the gastrointestinal tract following enterohepatic circulation. Other methods of enhancing the elimination of the toxins have been trialed; techniques such as hemodialysis, hemoperfusion, plasmapheresis, and peritoneal dialysis have occasionally yielded success, but overall do not appear to improve outcome. In patients developing liver failure, a liver transplant is often the only option to prevent death.
In his 1858 synopsis he even arranged lichens along an "algal‑to‑fungal continuum"—a speculative evolutionary ladder that cast the thallus as a transitional stage between algae and true fungi. Although soon eclipsed by Schwendener's dual‑symbiosis hypothesis, the idea shows that lichenologists were already grappling with gradations between the symbionts well before the composite nature of the organism was proved. Other botanists emphasised spores and propagules as diagnostic features. Britons William Lauder Lindsay (1851) and Henry Mudd (1861) proposed splitting genera by spore number, size and septation, while continental workers such as Abramo Bartolommeo Massalongo and Gustav Wilhelm Körber built whole generic frameworks around ascospore traits, sparking debate yet adding critical descriptors. By 1867 lichenology had grown from Linnaeus's single‑genus sketch into a specialized field, complete with dozens of experts, thousands of named species and a nascent multi-character taxonomy linking thallus form, anatomy and reproduction—just in time for the coming revolution that would redefine lichens as symbiotic fungi.
GOT1/cAST, the cytosolic isoenzyme derives mainly from red blood cells and heart. GOT2/mAST, the mitochondrial isoenzyme is present predominantly in liver. These isoenzymes are thought to have evolved from a common ancestral AST via gene duplication, and they share a sequence homology of approximately 45%. AST has also been found in a number of microorganisms, including E. coli, H. mediterranei, and T. thermophilus. In E. coli, the enzyme is encoded by the aspCgene and has also been shown to exhibit the activity of an aromatic-amino-acid transaminase (EC 2.6.1.57).
=== Nexon === In August 2014, Nexon announced Counter-Strike Nexon: Zombies, a free-to-play, zombie-themed spin-off, developed on the GoldSrc game engine. On September 23, 2014, an open beta was released on Steam. The game launched on October 7, 2014, featuring 50 maps and 20 game modes. The game features both player versus player modes such as team deathmatch, hostage rescue, and bomb defusal, alongside player versus environment modes such as cooperative campaign missions and base defending. Reception from critics was generally negative, with criticism aimed at the game's poor user interface, microtransactions, and dated graphics. On October 30, 2019, Counter-Strike Nexon: Zombies was renamed to Counter-Strike Nexon: Studio. On August 21, 2024, Counter-Strike Nexon: Studio was renamed to Counter-Strike Nexon. The game is set to be shut-down on September 30, 2026.
Sources: en.wikipedia.org
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.
The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.
Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.